Castle Biosciences (NASDAQ: CSTL) revenue
Castle Biosciences reported revenue of $344.2m for fiscal 2025, 3.7% more than in fiscal 2024 ($332.1m). Since fiscal 2018 its revenue has grown by 1,410.7%, an average growth of 47.4% a year.
Castle Biosciences has grown its revenue for 7 years in a row, and fiscal 2025 is the highest of its 8 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $344.2m | +3.7% | −$42.8m | −12.4% |
| 2024 | $332.1m | +51.1% | $8.7m | 2.6% |
| 2023 | $219.8m | +60.4% | −$68.0m | −30.9% |
| 2022 | $137.0m | +45.7% | −$72.9m | −53.2% |
| 2021 | $94.1m | +50.2% | −$40.1m | −42.6% |
| 2020 | $62.6m | +20.8% | −$6.5m | −10.4% |
| 2019 | $51.9m | +127.6% | $7.3m | 14.1% |
| 2018 | $22.8m | — | −$3.8m | −16.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Castle Biosciences revenue compared with its sector
By revenue for its latest fiscal year, Castle Biosciences ranks 213th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Castle Biosciences, 3.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 211th | MannKind | $349.0m | 22.2% |
| 212th | Inogen | $348.7m | 3.9% |
| 213th | Castle Biosciences | $344.2m | 3.7% |
| 214th | Tactile Systems Technology | $329.5m | 12.5% |
| 215th | Fulgent Genetics | $322.7m | 13.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Castle Biosciences
- How much revenue did Castle Biosciences make in fiscal 2025?
- Castle Biosciences reported revenue of $344.2m for fiscal 2025, compared with $332.1m in fiscal 2024.
- How much has the revenue of Castle Biosciences grown?
- Between fiscal 2018 and fiscal 2025 it went from $22.8m to $344.2m: 1,410.7% more, an average growth of 47.4% a year.
- What was the best year for revenue at Castle Biosciences?
- Of its last 8 fiscal years, fiscal 2025, with $344.2m.
- Where does Castle Biosciences rank in its sector by revenue?
- It ranks 213th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Castle Biosciences come from?
- From the annual report (Form 10-K) that Castle Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Castle Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Castle Biosciences: the Castle Biosciences page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.